Nautilus Biotechnology, Inc.(NAUT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NAUT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Nautilus Biotechnology, Inc. (NAUT), a Technology sector company. NAUT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Nautilus Biotechnology, Inc. reports net income of $-14.7M, free cash flow of $-13.6M. Top institutional holders of NAUT by reported 13-F value include a16z Capital Management, L.L.C., PERCEPTIVE ADVISORS, Cercano Management, based on the most recent SEC filings. NAUT trades on the Nasdaq exchange and files with the SEC under CIK 1808805. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAUT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nautilus Biotechnology, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-14.7M
Free Cash Flow
Q1 2026
$-13.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+7.3% YoYEPS (Diluted)
+7.8% YoYTotal Assets
-37.5% YoYOp. Cash Flow
+2.0% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-59.0M +7.3% | $-63.7M -9.9% | $-57.9M -15.1% | $-50.3M -222.1% | $-15.6M | — |
| EPS (Diluted) | $-0.47 +7.8% | $-0.51 -10.9% | $-0.46 +23.3% | $-0.60 -11.1% | $-0.54 | — |
| Total Assets | $191.1M -37.5% | $305.6M -12.7% | $350.1M -12.1% | $398.4M +368.7% | $85.0M | — |
| Operating Cash Flow | $-50.7M +2.0% | $-51.7M -12.9% | $-45.8M -16.7% | $-39.2M -180.4% | $-14.0M | — |
AI Insight: NAUT Financial Trends
Nautilus shows gradual improvement in cash burn with quarterly operating cash flow outflows declining from $15M to $11M, but equity base continues shrinking to $144M.
• Operating cash flow outflows improved from $15M in Q2 2024 to $11M in Q3 2025 before ticking up to $13M in Q1 2026.
• Net losses moderated from $18M in Q2 2024 to $14M in recent quarters, showing some stabilization.
• Equity declined consistently from $235M in Q2 2024 to $144M in Q1 2026, reflecting ongoing cash consumption.
⚠ Operating cash flow deteriorated in Q1 2026 to $13M outflow after improving to $11M in Q3 2025.
⚠ Equity base has shrunk $91M over eight quarters with no revenue generation visible yet.
AI Insight: NAUT Ratio Trends
ROE deteriorated sharply to -40.7% in Q1 2026, marking the worst profitability in nearly two years.
• ROE declined from -29.4% in Q3 2024 to -40.7% in Q1 2026, showing sustained losses.
• ROA weakened from -25.3% in Q3 2024 to -33.1% in Q1 2026, indicating poor asset utilization.
⚠ Q1 2026 ROE of -40.7% represents the worst quarterly performance since Q2 2024's -30.6%.
⚠ Missing operating margin and net profit margin data limits visibility into operational efficiency trends.
Get alerted when NAUT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Nautilus Biotechnology, Inc. including:
Top Institutional Holders of NAUT
a16z Capital Management, L.L.C.
$68.5M17,653,917 shPERCEPTIVE ADVISORS LLC
$48.9M12,594,211 shCercano Management LLC
$27.8M7,172,985 shVANGUARD CAPITAL MANAGEMENT LLC
$9.9M2,545,597 shClearstead Advisors, LLC
$9.0M2,329,784 shComprehensive Financial Management LLC
$8.6M2,207,619 shAMAZON COM INC
$5.7M1,457,055 shMILLENNIUM MANAGEMENT LLC
$4.9M1,273,383 shTikvah Management LLC
$2.8M726,895 shGEODE CAPITAL MANAGEMENT, LLC
$2.3M603,524 sh
| Fund | Value | Shares |
|---|---|---|
| a16z Capital Management, L.L.C. | $68.5M | 17,653,917 |
| PERCEPTIVE ADVISORS LLC | $48.9M | 12,594,211 |
| Cercano Management LLC | $27.8M | 7,172,985 |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.9M | 2,545,597 |
| Clearstead Advisors, LLC | $9.0M | 2,329,784 |
| Comprehensive Financial Management LLC | $8.6M | 2,207,619 |
| AMAZON COM INC | $5.7M | 1,457,055 |
| MILLENNIUM MANAGEMENT LLC | $4.9M | 1,273,383 |
| Tikvah Management LLC | $2.8M | 726,895 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.3M | 603,524 |
More Technology Companies
View all Technology →Put NAUT on your watchlist
Track score changes the day Nautilus Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NAUT a good stock to buy?
13F Pro's AI-powered analysis of Nautilus Biotechnology, Inc. (NAUT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NAUT are available on the NAUT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NAUT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NAUT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Nautilus Biotechnology, Inc.'s investment landscape.